Sioux Falls, SD, United States of America

Yoshimi Kuroiwa

USPTO Granted Patents = 20 (Patent Applications = 4)

CIPO Patents = 2

EPO Patents = 3 (Patent Applications = 1)

Average Co-Inventor Count = 4.6

ph-index = 8

Forward Citations = 139(Granted Patents)

Location History:

Takasaki, JP (2006)
Gumma, JP (2008)
Gunma, JP (2011 - 2014)
La Jolla, CA (US) (2018)
Sioux Falls, SD (US) (2008 - 2019)

Company Filing History:

10 out of 272

Kyowa Hakko Kirin Co., Limited

Kirin Pharma Kabushiki Kaisha

patents

4. 2 out of 215

Kirin Beer Kabushiki Kaisha

patents

5. 2 out of 47

Kirin Holdings Kabushiki Kaisha

patents

6. 2 out of 1,624

E. R. Squibb Sons, Inc.

where one patent can have more than one assignee

Years Active: 2006-2019

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10448622 - Human artificial chromosome containing human antibody lambda light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmission (2019-10-22),

2. 9902970 - Complex chromosome engineering for production of human antibodies in transgenic animals (2018-02-27),

3. 9775332 - Human artificial chromosome vector (2017-10-03),

4. 9499838 - Human artificial chromosome containing human antibody λ light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmission (2016-11-22),

5. 9315824 - Human artificial chromosome vector (2016-04-19),

6. 8703482 - Human artificial chromosome (HAC) vector (2014-04-22),

7. 8124406 - Method for modifying chromosomes (2012-02-28),

8. 7928285 - Method of producing xenogenous antibodies using a bovine (2011-04-19),

9. 7868223 - Method for modifying chromosomes (2011-01-11),

10. 7820878 - Production of ungulates, preferably bovines that produce human immunoglobulins (2010-10-26),

11. 7807863 - Transgenic bovine having reduced prion protein activity and uses thereof (2010-10-05),

12. 7803981 - Transgenic ungulates capable of human antibody production (2010-09-28),

13. 7491867 - Expression of xenogenous (human) immunoglobulins in cloned, transgenic ungulates (2009-02-17),

14. 7476536 - Artificial human chromosome containing human antibody a light chain gene (2009-01-13),

15. 7429690 - Transgenic bovines having reduced prion protein production (2008-09-30),

Title: The Innovations of Yoshimi Kuroiwa in Genetic Engineering

Introduction

Yoshimi Kuroiwa, based in Sioux Falls, SD, stands out as a prominent inventor in the field of genetic engineering. With a remarkable portfolio of 20 patents, his work significantly contributes to advancements in biotechnology, particularly in the area of human antibodies.

Latest Patents

Kuroiwa's most recent patents showcase his expertise in creating human artificial chromosomes. One of his notable inventions is a human artificial chromosome containing the human antibody lambda light chain gene, which is genetically transmissible to subsequent generations with high efficiency. This innovation includes methods for utilizing this chromosome to produce human antibodies via non-human animals, thereby advancing genetic studies. Another significant patent involves complex chromosome engineering aimed at the large-scale production of human antibodies through transgenic animals, yielding high concentrations of fully human IgG.

Career Highlights

Throughout his career, Kuroiwa has made substantial contributions to the field while working with renowned companies, including Kyowa Hakko Kirin Co., Limited and Sab, LLC. His work primarily focuses on advancing methodologies for antibody production and exploring genetic transmission methods.

Collaborations

Kuroiwa has collaborated with notable professionals in his field, including Kazuma Tomizuka and Isao Ishida. These collaborations have further enhanced the potential applications of his innovations and contributed to groundbreaking research in genetic engineering.

Conclusion

Yoshimi Kuroiwa's work exemplifies the innovative spirit of modern biotechnology, paving the way for future advancements in genetic research and human antibody production. His contributions continue to influence the scientific community and hold promise for numerous applications in medicine and research.

This text is generated by artificial intelligence and may not be accurate.